263 results on '"Stone, Everett"'
Search Results
2. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11
3. Leveraging intrinsic flexibility to engineer enhanced enzyme catalytic activity
4. Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance
5. Bypassing evolutionary dead ends and switching the rate-limiting step of a human immunotherapeutic enzyme
6. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
7. Enzyme-mediated depletion of serum L-Met abrogates prostate cancer growth via multiple mechanisms without evidence of systemic toxicity
8. Combinatorial Approaches to Enhance DNA Damage following Enzyme-Mediated Depletion of L-Cys for Treatment of Pancreatic Cancer
9. Non-canonical Glutamate-Cysteine Ligase Activity Protects against Ferroptosis
10. A missense mutation in ASRGL1 is involved in causing autosomal recessive retinal degeneration
11. A Genome-wide Haploid Genetic Screen Identifies Regulators of Glutathione Abundance and Ferroptosis Sensitivity
12. Author Correction: Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
13. CD8+ T cells regulate tumour ferroptosis during cancer immunotherapy
14. Three-Dimensional Structure of the Quorum-Quenching N-Acyl Homoserine Lactone Hydrolase from Bacillus thuringiensis
15. Reversal of indoleamine 2,3-dioxygenase–mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
16. Optimization of a nicotine degrading enzyme for potential use in treatment of nicotine addiction
17. Enzyme-mediated depletion of l-cyst(e)ine synergizes with thioredoxin reductase inhibition for suppression of pancreatic tumor growth
18. Supplementary Data from Cyst(e)inase–Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer
19. Figure S2 from Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11
20. Data from Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11
21. Supplementary Table from Cyst(e)inase–Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer
22. Data from Cyst(e)inase–Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer
23. Table S1 from Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11
24. Additional file 1 of Cysteine depletion sensitizes prostate cancer cells to agents that enhance DNA damage and to immune checkpoint inhibition
25. Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth
26. Enzymatic depletion of l‐Met using an engineered human enzyme as a novel therapeutic strategy for melanoma.
27. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells
28. Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells
29. Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy
30. Recombinant Human Arginase Toxicity in Mice Is Reduced by Citrulline Supplementation
31. Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors.
32. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants
33. Bioengineered Human Arginase I with Enhanced Activity and Stability Controls Hepatocellular and Pancreatic Carcinoma Xenografts
34. Cyst(e)inase–Rapamycin Combination Induces Ferroptosis in Both In Vitro and In Vivo Models of Hereditary Leiomyomatosis and Renal Cell Cancer
35. Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency
36. Promiscuous Partitioning of a Covalent Intermediate Common in the Pentein Superfamily
37. GFP Reporter Screens for the Engineering of Amino Acid Degrading Enzymes from Libraries Expressed in Bacteria
38. Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: Dimethylargininase and peptidylarginine deiminase
39. Engineering Reduced-Immunogenicity Enzymes for Amino Acid Depletion Therapy in Cancer
40. Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.
41. Conformational Dynamics Contribute to Substrate Selectivity and Catalysis in Human Kynureninase
42. The Force Awakens: Illuminating the Role of Kynurenine in Cancer Progression and Treatment
43. Cysteine depletion induces pancreatic tumor ferroptosis in mice
44. Quantifying the Dynamics of L-Kynureninase Orthologs during Catalysis Using HDX-MS
45. Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11
46. Abstract LB-A18: The frequent tumor deletion of MTAP is a newly recognized potent immune checkpoint that is effectively reversed by a human methylthioadenosine degrading drug candidate
47. “Induction of pancreatic tumor-selective ferroptosis through modulation of cystine import”
48. Abstract 2996: Systemic depletion of L-methionine with an engineered human enzyme for the treatment of melanoma
49. CD8+ T cells regulate tumor ferroptosis by targeting the system xc− during cancer immunotherapy
50. Abstract B008: Treatment of IDO1 and TDO2 positive tumors with a kynurenine-degrading enzyme: A highly differentiated approach from IDO1 inhibition
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.